And Lilly was well ahead of the pack, fuelled by Alzheimer’s hopes.
Shareholders are rewarding the kinds of companies they punished a year ago.
Covid-19 vaccine developers stand out as global drug stocks tread water in the first quarter.
A rollercoaster year for biopharma ended with investors firmly deciding that the pandemic was an opportunity, not a threat.
The pandemic provided the best and worst of times for smid-cap medtechs.
In the second half of 2020 medtech began a tentative – and possibly short-lived – recovery.
The pandemic remains the dominant storyline for drug stocks at the nine-month mark, with Vertex and Horizon rare non-Covid-related risers.
Global drug stocks enthusiastically joined the recovery on the financial markets in the second quarter, more than offsetting earlier declines.
Mid- and small-cap medtechs find themselves at the mercy of government responses to the Covid-19 pandemic.